In Segment A, members will acquire various doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 might be given as "include-on" therapy. In Section C, https://abbv-744-brd4-inhibitor-m80134.blogunteer.com/31225041/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained